Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 3.39 0.30% 0.01
BLCM closed down 3.7 percent on Thursday, January 17, 2019, on 69 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BLCM trend table...

Date Alert Name Type % Chg
Jan 17 Inside Day Range Contraction 0.30%
Jan 17 Wide Bands Range Expansion 0.30%
Jan 16 Wide Bands Range Expansion -3.42%
Jan 15 20 DMA Support Bullish 1.50%
Jan 15 Doji - Bullish? Reversal 1.50%
Jan 15 Wide Bands Range Expansion 1.50%
Jan 15 Down 3 Days in a Row Weakness 1.50%
Jan 14 Weak + Overbought Other 1.19%
Jan 14 Wide Bands Range Expansion 1.19%
Jan 14 Overbought Stochastic Strength 1.19%

Older signals for BLCM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Is BLCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.26
52 Week Low 2.74
Average Volume 504,848
200-Day Moving Average 6.1664
50-Day Moving Average 3.849
20-Day Moving Average 3.286
10-Day Moving Average 3.484
Average True Range 0.2867
ADX 10.75
+DI 19.8709
-DI 17.0059
Chandelier Exit (Long, 3 ATRs ) 3.1099
Chandelier Exit (Short, 3 ATRs ) 3.6001
Upper Bollinger Band 3.8052
Lower Bollinger Band 2.7668
Percent B (%b) 0.59
BandWidth 31.60073
MACD Line -0.1027
MACD Signal Line -0.1591
MACD Histogram 0.0564
Fundamentals Value
Market Cap 112.3 Million
Num Shares 33.2 Million
EPS -2.94
Price-to-Earnings (P/E) Ratio -1.15
Price-to-Sales 975.18
Price-to-Book 2.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.68
Resistance 3 (R3) 3.70 3.63 3.63
Resistance 2 (R2) 3.63 3.55 3.62 3.61
Resistance 1 (R1) 3.50 3.50 3.47 3.48 3.60
Pivot Point 3.43 3.43 3.41 3.42 3.43
Support 1 (S1) 3.30 3.35 3.27 3.28 3.16
Support 2 (S2) 3.23 3.30 3.22 3.15
Support 3 (S3) 3.10 3.23 3.13
Support 4 (S4) 3.08